A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/22 (2006.01) A61K 38/04 (2006.01) A61P 3/00 (2006.01) A61P 9/00 (2006.01) A61P 11/00 (2006.01) A61P 25/28 (2006.01) A61P 31/00 (2006.01) A61P 31/18 (2006.01) A61P 35/00 (2006.01) A61P 37/00 (2006.01)
Patent
CA 2699084
The present invention is directed to the use of the peptide compound Gly-Leu- Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys- Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met- Ser-Gly-Leu-Gly-Cys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
La présente invention concerne l'utilisation du composé peptidique Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-lle-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH en tant qu'agent thérapeutique pour la prophylaxie et/ou le traitement du cancer, de maladies auto-immunes, de maladies fibrotiques, de maladies inflammatoires, de maladies neurodégénératives, de maladies infectieuses, de maladies pulmonaires, de maladies cardiovasculaires et de maladies métaboliques. De plus, la présente invention concerne des compositions pharmaceutiques, de préférence sous forme d'un lyophilisat ou d'une solution tampon liquide ou d'une formulation de lait maternel artificiel ou d'un substitut de lait maternel contenant le peptide Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-lle-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH, éventuellement associé à au moins un support pharmaceutiquement acceptable, un cryoprotecteur, un lyoprotecteur, un excipient et/ou un diluant.
Bacher Gerald
Bevec Dorian
Cavalli Fabio
Cavalli Vera
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Mondobiotech Laboratories Ag
LandOfFree
Use of cnp-22, alone1 or in combination with physalemin, as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cnp-22, alone1 or in combination with physalemin, as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cnp-22, alone1 or in combination with physalemin, as... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1939250